Pharma and Social Media: Progress!

This week, I attended two conferences relating to pharma and eCommunications/Social Media. The MDRx conference (sponsored by IIR) was in Philly, and the Social Communications and Healthcare Case Studies and Roundtable event was held in NYC.
Instead of writing my usual post-event description, I decided to just spill my guts a bit on where things are [...]

Read Full Post »

An e-Vent on Pharma Social Media

I’m at a conference on Physician Relationship Management (MDRx). As usual, we’re talking e-marketing, social media, and fear. If  you know pharma, you know that anything new is embraced with enthusiastic expressions of…terror.
Often, the starting points for these discussions are the following:
1. How are we going to do this and keep clean on the [...]

Read Full Post »

Today’s Top Pharma News 071609

FDA to Zeltia: NO – An FDA advisory committee has handed Spain’s Zeltia a crushing blow, deciding against a combination therapy that includes its lead cancer drug Yondelis (trabectedin) by a vote of 14 to 1. The news cost Zeltia 35 percent of its share price…more
FDA to Shire: Fast-track – Shire plc, the global specialty biopharmaceutical [...]

Read Full Post »

Today’s Top News in Pharma 071509

FDA to Watson on 24-week Trelstar: Ummm, not yet. Oh, and to Bayer and J&J for Xarelto: Ummmm, not yet.
Bayer’s Yaz and blood clots – the legal wrangling continues.
Solvay selling out on pharma, narrows it down to 2 bidders – Solvay has whittled down the list of bidders for its pharmaceuticals business to Nycomed, the [...]

Read Full Post »

Today’s Top Pharma News 71309

Finally – FDA approves DSI/Lilly blood thinner Effient. Narrow indication with warnings, however – The approval makes Lilly’s Effient the first real competition to the blood thinner Plavix, the world’s second-best selling medication made by Sanofi-Aventis and Bristol-Myers Squibb…more
Debate ignited over newer vs. older schizophrenia drugs – Schizophrenia patients given a cheap older drug are [...]

Read Full Post »

Today’s Top Pharma News 071009

Roche-Genentech – the cuts begin – Anxiety rippled through Genentech this week as the Swiss drug firm Roche began to cut rank-and-file jobs as it folds the South San Francisco biotech firm into its global operations…more
Sciele-Victory link-up: Nah, guess not.
J&J, Vertex, and biodollars.
Merck gets expanded approval for HIV drug – The Food and Drug Administration [...]

Read Full Post »

A Pharma Marketing Assortment Pack

Physican on-line network Sermo about the AMA: Wow – Sermo polled the 100,000 US physicians in our community as to what they thought of the AMA.  Within five days, over 4,100 US physicians voted on the poll and discussed it in over 700 comments.  The results were nothing short of  stunning – 89% of those [...]

Read Full Post »

Today’s Top News in Pharma 070909

Study ended early – who’s the winner? Zetia or Niaspan?
Could New Jersey lose its pharma edge?
BiogenIdec gets a fast track – Biogen Idec Inc., a Cambridge company known for its multiple sclerosis drugs, said that US Food and Drug Administration has granted it Fast Track designation for a potential treatment of relapsing multiple sclerosis…more
———-
Subscribe to [...]

Read Full Post »

Today’s Top News in Pharma 070809

Amgen’s big win – Amgen’s experimental denosumab is more effective than Novartis’ blockbuster Zometa in preventing advanced breast cancer from damaging bone, Amgen said in a press release Tuesday…more
Wyeth’s Prevnar: how about 25% off? – What’s the right amount of the childhood vaccine Prevnar? A study published in JAMA today suggests that three doses may [...]

Read Full Post »

CBI’s Emerging Media conference re-cap

Last week, I had the pleasure of attending a conference on Emerging Media in Pharma, sponsored by the good folks at CBI. It was held in a Doubletree Hotel in Philly – the majority of pharma-themed conferences are now held in Philly, it seems (with a few scattering into Princeton NJ, or other nearby locales).
My [...]

Read Full Post »